Single Source: National Longitudinal Study of Adolescent to Adult (Add) Health Wave VII (U01 Clinical Trial Not Allowed)
ID: 358815Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Public and State Controlled Institutions of Higher Education

Funding Category

Income Security and Social Services

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358815

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-001.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for the National Longitudinal Study of Adolescent to Adult Health (Add Health) Wave VII, focusing on research related to aging and Alzheimer’s disease. This cooperative agreement is specifically aimed at the University of North Carolina at Chapel Hill and seeks to continue essential study activities such as mixed-mode surveys, in-home health visits, and data dissemination, while also enhancing the study with additional aging biomarkers. The Add Health study, which began in 1994-1995, tracks individuals born primarily from 1976 to 1982 and will now evaluate midlife factors impacting Alzheimer’s risk at ages 44-49, aiming to deepen the understanding of health disparities related to aging and Alzheimer’s disease. The total funding available for this non-competitive award is estimated at $13,100,000 over a maximum period of five years, with a submission deadline of October 17, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-26-001.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AG-26-001-Full-Announcement.html
    RFA-AG-26-001.html
    The National Institutes of Health (NIH) is issuing a funding opportunity for the National Longitudinal Study of Adolescent to Adult Health (Add Health) Wave VII, with a focus on researching aging and Alzheimer’s disease. This single-source cooperative agreement is aimed specifically at the University of North Carolina at Chapel Hill and intends to continue core activities such as mixed-mode surveys, health visits, and data dissemination, while also developing enhancements like the assay of additional aging biomarkers. The study, initially launched in 1994-1995, tracks individuals born primarily from 1976 to 1982 and will now assess midlife factors impacting Alzheimer’s risk at a critical age range of 44-49. The goal is to enrich understanding of longitudinal factors affecting health disparities related to aging, Alzheimer’s disease, and related dementias. With an estimated total of $13,100,000 available for one award over a maximum period of five years, this non-competitive funding emphasizes comprehensive strategies for data collection and sharing. Timely submission protocols and strict compliance with application guidelines are mandated, ensuring high standards for research quality and data integrity. The study aims to develop a data resource beneficial to understand life course determinants of aging and associated health outcomes, reinforcing the NIH’s investment in public health research.
    Similar Opportunities
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.
    Adult-Adolescent Brain Cognitive Development (A-ABCD) Study Renewal-Research Project Sites (U01)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the renewal of the Adult-Adolescent Brain Cognitive Development (A-ABCD) Study, specifically for research project sites under the U01 cooperative agreement mechanism. This initiative aims to continue the groundbreaking ABCD study, which is the largest long-term investigation of brain development and child and adolescent health in the U.S., by following the original cohort of nearly 12,000 participants into their emerging adulthood to assess various health outcomes. The study utilizes advanced technologies, including brain scans and wearable sensors, to explore how young adult experiences influence brain development and related social and health outcomes. Interested organizations that were funded through RFA-DA-20-002 are encouraged to prepare for this opportunity, with the estimated synopsis posting date on February 6, 2026, and a projected award date of April 1, 2027. For further inquiries, potential applicants can contact Dr. Bethany Deeds at deedsb@nida.nih.gov or by phone at 301-402-1935.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Multidisciplinary Studies of HIV/AIDS and Aging," aimed at exploring the intersection of HIV and aging. This initiative seeks to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, while also improving strategies for testing, prevention, and treatment of HIV-related health complications. Given the increasing number of older adults living with HIV, this research is crucial for addressing public health challenges and improving healthcare delivery across diverse populations. The funding supports exploratory research under the R21 mechanism, with a maximum budget of $275,000 for two years, and applications are due between May 2025 and January 2027. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-355.html.
    Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for multidisciplinary research on HIV/AIDS and aging through the R21 Exploratory/Developmental Research Grant program. This initiative invites applications that aim to enhance the understanding of the biological, clinical, and socio-behavioral aspects of aging in the context of HIV infection, with specific objectives to improve prevention, testing, treatment strategies, and management of HIV-related health issues in diverse populations, particularly older adults aged 70 and above. The grant provides funding of up to $275,000 for a two-year period, with key submission dates starting April 4, 2024, and a closing date for applications set for January 7, 2027. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Approaches to Advance Precision Aging and Cognitive Health
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) titled "Novel Approaches to Advance Precision Aging and Cognitive Health," aimed at soliciting applications that leverage innovative study designs and methods, including machine learning and artificial intelligence, to enhance cognitive health in older adults. This initiative seeks to develop personalized prevention plans and interventions by discovering health and function profiles at the individual level, encompassing research from cellular to societal levels. The grant will utilize the R01 activity code, with applications not currently being solicited; however, potential applicants are encouraged to begin forming collaborations and project ideas in anticipation of the funding opportunity. For further inquiries, interested parties may contact Dr. Molly Wagster at wagsterm@nia.nih.gov or by phone at 301-496-9350. The estimated synopsis post date is August 6, 2026, with a close date of October 6, 2026, and an anticipated award date of July 6, 2027.
    Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Healthcare for Older Adults from Populations that Experience Health Disparities" under the R01 Clinical Trial Optional grant program. This initiative aims to enhance the science and implementation of healthcare research focused on older adults from populations facing health disparities, specifically targeting improvements in screening, diagnostic, and clinical care guidelines, as well as fostering shared decision-making between clinicians and patients. The research is particularly significant for addressing the unique health challenges encountered by older adults from racial and ethnic minorities and underserved communities, emphasizing innovative care solutions that consider social determinants of health. Interested applicants can find more information and apply through the NIH Grants website, with the application opening on January 5, 2025, and a close date set for January 7, 2028. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing or treating Alzheimer's disease (AD). This funding opportunity focuses on activities such as medicinal chemistry, pharmacokinetics, formulation development, and initial Phase I clinical testing, addressing the urgent public health challenge posed by AD, which currently affects approximately 6.7 million individuals in the U.S. Eligible applicants include a diverse range of organizations, with a funding ceiling of $1.5 million per year, and the application process is set to begin in January 2025, with a closing date of November 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Multidisciplinary Studies of HIV/AIDS and Aging," inviting applications for research that explores the intersection of HIV and aging. The primary objectives of this grant are to enhance understanding of the biological, clinical, and socio-behavioral aspects of aging in individuals living with HIV, as well as to improve strategies for testing, preventing, and treating HIV and managing related health complications. This funding opportunity is significant for advancing health interventions for older adults affected by HIV, with eligible applicants including a wide range of institutions such as higher education entities, community organizations, and tribal governments. Interested parties should note that the application deadline is May 7, 2027, and can find further details and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-091.html.